AbbVie Inc. (ABBV) Lifted to “Strong-Buy” at BidaskClub

BidaskClub upgraded shares of AbbVie Inc. (NYSE:ABBV) from a buy rating to a strong-buy rating in a research report released on Saturday.

Other equities analysts have also issued research reports about the stock. SunTrust Banks, Inc. reiterated a buy rating and set a $95.00 price objective on shares of AbbVie in a research report on Wednesday, September 13th. Vetr upgraded shares of AbbVie from a hold rating to a buy rating and set a $76.28 target price for the company in a report on Wednesday, July 26th. Jefferies Group LLC restated a buy rating and issued a $94.00 target price (up previously from $92.00) on shares of AbbVie in a report on Monday, July 17th. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a $100.00 target price (up previously from $85.00) on shares of AbbVie in a report on Friday, September 8th. Finally, Piper Jaffray Companies restated a buy rating and issued a $85.00 target price on shares of AbbVie in a report on Thursday, August 3rd. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average target price of $93.68.

AbbVie (ABBV) opened at $94.75 on Friday. AbbVie has a 12-month low of $58.60 and a 12-month high of $98.26. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. The company has a market cap of $149,650.00, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 1.32 and a beta of 1.52.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same quarter last year, the business earned $1.21 earnings per share. AbbVie’s quarterly revenue was up 8.8% compared to the same quarter last year. equities research analysts forecast that AbbVie will post 5.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AbbVie Inc. (ABBV) Lifted to “Strong-Buy” at BidaskClub” was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/abbvie-inc-abbv-lifted-to-strong-buy-at-bidaskclub/1777318.html.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend is Thursday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is currently 61.84%.

In other AbbVie news, EVP Michael Severino sold 25,633 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the transaction, the executive vice president now owns 114,922 shares of the company’s stock, valued at approximately $10,881,964.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares in the company, valued at approximately $7,360,537.85. The disclosure for this sale can be found here. Insiders have sold a total of 58,932 shares of company stock worth $5,379,432 in the last three months. Insiders own 0.23% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Savant Capital LLC increased its position in AbbVie by 1.3% during the 2nd quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock valued at $4,433,000 after purchasing an additional 793 shares during the period. Princeton Capital Management Inc. purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $1,394,000. Accident Compensation Corp grew its position in shares of AbbVie by 24.7% in the 1st quarter. Accident Compensation Corp now owns 66,200 shares of the company’s stock worth $4,314,000 after buying an additional 13,100 shares during the last quarter. Investec Asset Management LTD grew its position in shares of AbbVie by 3.6% in the 1st quarter. Investec Asset Management LTD now owns 166,978 shares of the company’s stock worth $10,880,000 after buying an additional 5,801 shares during the last quarter. Finally, Palisade Asset Management LLC grew its position in shares of AbbVie by 17.9% in the 2nd quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after buying an additional 10,381 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.